Solve Therapeutics: $120 Million Secured To Advance Next Generation ADC Pipeline And Diagnostic Platform
By Amit Chowdhry ● Nov 18, 2025
Solve Therapeutics has raised $120 million in an oversubscribed financing round that will significantly accelerate the clinical development of its antibody drug conjugate programs and expand its proprietary CloakLink linker platform. The funding was led by Yosemite with participation from Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., and SymBiosis, along with the company’s existing backers, including Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, General Atlantic, and Surveyor Capital. This new infusion brings Solve’s total capital raised to $321 million following a $75 million round completed in late 2024.